DUBLIN, Ireland — Research and Markets (http://www.researchandmarkets.com/reports/c43328) has announced the addition of the latest report from Espicom Business Intelligence “Merck & Co Pharmaceutical Company Intelligence Report” to their offering.
Established in 1891, Merck & Co discovers, develops, manufactures and markets vaccines and pharmaceutical medicines to address unmet medical needs. The company operates on a global basis and is represented in more than 200 countries. Merck’s headquarters are based in Whitehouse Station, NJ. zocor.
Current Growth Drivers
Most Popular
10 Jobs That Pay $30 An Hour
5 Regular Mistakes In Public Speaking
13 Job Interview Mistakes To Avoid
Public Speaking: 7 Secrets Of Great Public Speakers
3 Questions No Job Seeker Ever Wants To Be Asked?
Merck currently markets six blockbuster products with sales in excess of US$1 billion, however, due to patent expiries and increasing competition in certain markets, only four of these will form the basis of future sales growth:
Cozaar (losartan potassium) was the first angiotensin-II receptor antagonist selective for AT1 receptors to be developed for the treatment of hypertension. It was jointly developed with DuPont Merck (now Bristol-Myers Squibb), as was Hyzaar, a combination of Cozaar and hydrochlorothiazide.
Zetia/Ezetrol (ezetimibe), a cholesterol absorption inhibitor, was developed by the Merck/Schering-Plough joint venture and is indicated for the treatment of hypercholesterolaemia.
Vytorin/Inegy (ezetimibesimvastatin) is a fixed-combination tablet that offers a novel approach to cholesterol management. It was jointly developed and launched by the Merck/Schering-Plough joint venture.
Singulair (montelukast) is a once-daily, long-acting oral leukotriene D4-receptor antagonist indicated for the treatment of asthma.
Cancidas (caspofungin acetate) is a water-soluble semi-synthetic agent derived from a fermentation product discovered at Merck’s laboratories in Madrid. It acts by inhibiting glucan synthase, the enzyme responsible for maintaining the fungal cell wall and is thus fungicidal against a broad range of pathogens including those that have become resistant to currently-used antifungal drugs.
Key Topics Covered Include:
- Principal Operating Results
- Latest Results
- Current Growth Drivers
- Key Late-Phase Products Reaching the Market Place
- Key Late-Stage Products
- Key Early-Stage Products
- Financial Performance 2005
- Sales and Market Position
- Capital Expenditure
- Capital Expenditure By Function
- R&D Expenditure
- Divisional Performance
- Vioxx/Ceoxx
- R&D Strategy
- Key R&D Projects
- R&D Pipeline Overview
- Discontinued R&D projects
For more information visit http://www.researchandmarkets.com/reports/c43328
COPYRIGHT 2006 Business Wire
COPYRIGHT 2008 Gale, Cengage Learning